title: Reduction of bacterial translocation with oral fibroblast growth factor and sucralfate.
abstract: The aim of this study was to evaluate the ability of basic fibroblast growth factor (bFGF) and sucralfate to prevent bacterial translocation after burn injury. Four groups of Balb/c mice (n = 10/group) were treated by gavage with bFGF (10 micrograms/kg/d), sucralfate (15 mg/kg/d), bFGF plus sucralfate, or saline for 4 days prior to receiving a gavage with 1 x 10(10) 14C-radiolabeled Escherichia coli and a 20% full-thickness burn. Four hours after burn, the mesenteric lymph nodes, liver, spleen, and blood were harvested aseptically. For each tissue, the number of viable bacteria and radionuclide counts of the translocated 14C-labeled E. coli were measured, and the percentage of translocated organisms that remained alive was calculated. The results indicated that treatment with either bFGF or sucralfate alone had a partial effect on translocation, whereas the combined treatment with bFGF plus sucralfate significantly decreased the magnitude of translocation in all tested tissues (p < 0.05, ANOVA), which was associated with complete preservation of gut mucosal integrity. None of the treatments affected the ability of the host to kill translocated bacteria when the results were compared with those of the controls. The additive effect of the combined therapy may be due to the high affinity of sucralfate for bFGF, decreasing the degradation of bFGF by gastric acid.
authors.affiliation: Department of Surgery, University of Cincinnati, School of Medicine, Ohio.
authors.forename: L
authors.initials: L
authors.lastname: Gianotti
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: R
authors.initials: R
authors.lastname: Fukushima
authors.forename: T
authors.initials: T
authors.lastname: Pyles
mesh_terms: D000818:Animals; D002056:Burns / Q000382:microbiology*; D002250:Carbon Radioisotopes; D002465:Cell Movement; D004064:Digestive System / Q000382:microbiology*; D004926:Escherichia coli / Q000187:drug effects / Q000502:physiology; D004927:Escherichia coli Infections / Q000517:prevention & control*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D008099:Liver / Q000382:microbiology; D008198:Lymph Nodes / Q000382:microbiology; D008643:Mesentery / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000382:microbiology; D013392:Sucralfate / Q000627:therapeutic use*
chemical_list: D002250:Carbon Radioisotopes; D016222:Fibroblast Growth Factor 2; D013392:Sucralfate